Catatonia: Symptoms, Causes, Diagnosis, and Treatment

Catatonia is a complex psychomotor syndrome characterized by a range of motor, behavioral, and autonomic abnormalities. It is not a standalone psychiatric disorder but rather a clinical syndrome that can occur in the context of medical conditions, mood disorders, psychotic disorders, neurodevelopmental disorders, and other clinical states. The hallmark features include marked alterations in movement — from complete immobility and unresponsiveness to excessive, purposeless motor activity.

Historically, catatonia was considered a subtype of schizophrenia, but modern clinical understanding has shifted dramatically. The DSM-5-TR recognizes catatonia as a specifier that can be applied across multiple conditions, as a feature associated with another medical condition, and as an "unspecified" category when the underlying cause is not yet identified. This reclassification reflects decades of research showing that catatonia occurs far more frequently in mood disorders — particularly bipolar disorder and major depressive disorder — than in schizophrenia.

Prevalence estimates vary depending on the clinical setting and population studied. Research suggests that catatonia is present in approximately 9–17% of acute psychiatric inpatients, though it is widely regarded as underdiagnosed. In medical and neurological settings, prevalence estimates range from 7–15% of patients in intensive care units with unexplained altered mental status. Among individuals with autism spectrum disorder, catatonic features have been reported in an estimated 12–18% of adolescents and adults. Catatonia affects individuals of all ages, though certain subtypes are more common in specific populations.

The DSM-5-TR requires the presence of three or more of the following twelve psychomotor features for a clinical diagnosis of catatonia:

• Stupor: No psychomotor activity; the person is not actively relating to the environment despite being awake.
• Catalepsy: Passive induction of a posture held against gravity — the person's limbs remain in whatever position they are placed, as if they were made of wax.
• Waxy flexibility: Slight, even resistance to repositioning by the examiner, with the limb staying in the new position.
• Mutism: No or very little verbal response, not attributable to known aphasia.
• Negativism: Opposition to or no response to instructions or external stimuli.
• Posturing: Spontaneous and active maintenance of a posture against gravity.
• Mannerism: Odd, circumstantial caricature of normal actions.
• Stereotypy: Repetitive, abnormally frequent, non-goal-directed movements.
• Agitation: Motor agitation not influenced by external stimuli.
• Grimacing: Involuntary, sustained facial contractions.
• Echolalia: Mimicking another's speech.
• Echopraxia: Mimicking another's movements.

Clinically, catatonia is often described in terms of three subtypes, though these are not formal DSM categories:

• Retarded (akinetic) catatonia: The most common presentation, characterized by immobility, mutism, staring, posturing, and withdrawal. This is the "classic" image of catatonia most people recognize.
• Excited catatonia: Characterized by excessive purposeless motor activity, agitation, combativeness, impulsivity, and autonomic instability. This form is dangerous and can be mistaken for acute mania or delirium.
• Malignant catatonia: A life-threatening variant featuring fever, autonomic dysregulation (tachycardia, labile blood pressure, diaphoresis), rigidity, altered consciousness, and elevated creatine kinase levels. This constitutes a medical emergency.

Warning signs that should prompt urgent evaluation include sudden onset of immobility or mutism, refusal to eat or drink (which can lead to dehydration and malnutrition), high fever with rigidity, and rapid deterioration in consciousness. A person who was previously functioning and suddenly becomes mute, still, and unresponsive — yet appears awake — should be assessed for catatonia immediately.

Catatonia is best understood as a final common pathway — a syndrome that emerges from disruption in specific brain circuits regardless of the triggering condition. The neurobiology is not yet fully elucidated, but leading hypotheses focus on dysfunction in cortico-basal ganglia-thalamocortical circuits and abnormalities in neurotransmitter systems, particularly gamma-aminobutyric acid (GABA), dopamine, and glutamate.

Psychiatric conditions are the most common context for catatonia:

• Mood disorders: Bipolar disorder (particularly manic and mixed episodes) and major depressive disorder account for the majority of catatonia cases — research suggests approximately 20–30% of catatonia presentations are associated with mood disorders.
• Psychotic disorders: Schizophrenia and schizoaffective disorder are associated with catatonia, though less frequently than historically assumed.
• Neurodevelopmental disorders: Autism spectrum disorder is increasingly recognized as a significant risk factor, particularly in adolescents and young adults.

Medical and neurological conditions that can cause catatonia include:

• Autoimmune encephalitis, particularly anti-NMDA receptor encephalitis
• Viral and bacterial encephalitis
• Metabolic disturbances (hepatic encephalopathy, hypercalcemia, diabetic ketoacidosis)
• Epilepsy, particularly nonconvulsive status epilepticus
• Stroke and other focal brain lesions
• Systemic lupus erythematosus and other autoimmune conditions

Substance-related causes include withdrawal from benzodiazepines or alcohol, use of certain illicit substances, and medication-induced catatonia. Notably, neuroleptic malignant syndrome (NMS) — caused by dopamine-blocking medications — is considered by many experts to be a drug-induced form of malignant catatonia.

Risk factors that increase vulnerability include a history of previous catatonic episodes (recurrence rates are significant), female sex (some studies suggest a higher prevalence in women), pre-existing mood or psychotic disorders, autism spectrum disorder, and exposure to high-potency antipsychotics. Abrupt discontinuation of benzodiazepines or other GABAergic agents is a well-recognized precipitant.

Diagnosis of catatonia is clinical and bedside — there is no blood test, brain scan, or biomarker that confirms the syndrome. This reliance on clinical observation is both its strength (it can be diagnosed rapidly) and its weakness (it is frequently missed).

The most widely used standardized assessment tool is the Bush-Francis Catatonia Rating Scale (BFCRS), a 23-item clinician-administered scale that evaluates the presence and severity of catatonic signs. The first 14 items constitute a screening instrument; a score of two or more positive items on the screening portion has high sensitivity for catatonia. The full scale is used to track treatment response.

The DSM-5-TR diagnostic criteria require the presence of at least three of the twelve cardinal features (listed above). The DSM-5-TR provides three coding options:

• Catatonia associated with another mental disorder (e.g., catatonia as a specifier for bipolar disorder, major depressive disorder, or schizophrenia)
• Catatonic disorder due to another medical condition
• Unspecified catatonia — used when the etiology is unclear or documentation is incomplete

A critical diagnostic step is the lorazepam challenge test (also called the benzodiazepine challenge). The administration of 1–2 mg of intravenous or intramuscular lorazepam typically produces a marked improvement in catatonic signs within minutes in many patients. A positive response — defined as a significant reduction in BFCRS scores within 5–10 minutes — strongly supports the diagnosis and simultaneously guides treatment. However, a negative response does not rule out catatonia.

Differential diagnosis is essential and often complex. Conditions that can mimic catatonia include:

• Neuroleptic malignant syndrome
• Delirium
• Nonconvulsive status epilepticus
• Locked-in syndrome
• Akinetic mutism from frontal lobe lesions
• Severe Parkinson's disease or parkinsonism
• Stiff-person syndrome

A thorough medical workup is essential and typically includes complete blood count, comprehensive metabolic panel, creatine kinase, thyroid function tests, urinalysis, toxicology screen, brain imaging (MRI preferred), and electroencephalography (EEG) to rule out seizure activity. In cases with suspected autoimmune encephalitis, cerebrospinal fluid analysis and autoimmune antibody panels are indicated.

Catatonia is one of the most treatment-responsive conditions in all of psychiatry when identified promptly and managed appropriately. The two primary evidence-based treatments are benzodiazepines and electroconvulsive therapy (ECT).

Benzodiazepines — particularly lorazepam — are the first-line treatment for catatonia. Lorazepam acts on GABA-A receptors, and its effectiveness in catatonia is one of the strongest pieces of evidence supporting the GABAergic dysfunction hypothesis. Treatment typically begins at 1–2 mg administered intravenously, intramuscularly, or orally, with doses titrated upward as needed. Many patients require total daily doses of 6–16 mg, and some require even higher doses. Response rates to benzodiazepines are approximately 60–80% for non-malignant catatonia. The response is often rapid — sometimes dramatic improvement occurs within hours. Importantly, once catatonia resolves, benzodiazepines are typically continued and then tapered very gradually, as abrupt discontinuation can precipitate relapse.

Electroconvulsive therapy (ECT) is the definitive treatment for catatonia and is considered the gold standard, particularly for:

• Patients who do not respond to adequate benzodiazepine trials
• Malignant catatonia (a medical emergency)
• Cases where rapid resolution is clinically urgent (e.g., life-threatening dehydration, pulmonary embolism risk from immobility)

ECT response rates in catatonia are approximately 80–100% in published case series, making it one of the most effective applications of ECT in all of medicine. Bilateral electrode placement is generally preferred, and a course typically involves 6–20 sessions. Some patients require maintenance ECT to prevent recurrence.

Important treatment considerations:

• Antipsychotics should be used with extreme caution in catatonia, particularly first-generation (typical) antipsychotics. These dopamine-blocking agents can worsen catatonia and precipitate malignant catatonia or neuroleptic malignant syndrome. If antipsychotic treatment is necessary for an underlying psychotic disorder, lower-potency second-generation agents are generally preferred, but only after catatonic features have resolved with benzodiazepines or ECT.
• Supportive care is critical during acute catatonia. This includes hydration, nutrition (via nasogastric tube if the patient is unable to eat), prevention of deep vein thrombosis (from immobility), skin care to prevent pressure ulcers, and monitoring for aspiration.
• Emerging treatments under investigation include NMDA receptor modulators such as amantadine and memantine, and the glutamate modulator topiramate. Zolpidem, a GABA-A receptor agonist, has shown promise in case reports for both diagnosis and treatment, though rigorous controlled trials are lacking.

Treatment of the underlying condition is equally important. Catatonia secondary to an autoimmune encephalitis, for example, requires immunotherapy. Catatonia in the context of bipolar disorder requires mood-stabilizing treatment after the acute catatonic episode resolves.

The prognosis for catatonia is generally favorable when the condition is recognized and treated promptly. The majority of patients with non-malignant catatonia respond well to benzodiazepines, ECT, or both. Complete resolution of catatonic signs is achievable in most cases.

However, several factors influence outcomes:

• Speed of recognition and treatment: Delayed diagnosis is the single greatest risk factor for poor outcomes. Untreated catatonia can progress from retarded catatonia to malignant catatonia, with potentially fatal consequences.
• Underlying etiology: Catatonia associated with mood disorders tends to have the best prognosis. Catatonia secondary to schizophrenia or chronic medical conditions may be more treatment-resistant and prone to recurrence.
• Malignant catatonia: Without aggressive treatment, malignant catatonia carries a mortality rate estimated at 10–20%, primarily from cardiovascular collapse, renal failure, or disseminated intravascular coagulation. With modern ICU care and early ECT, mortality has decreased significantly but remains a serious concern.
• Recurrence: Catatonia can recur, particularly if the underlying psychiatric or medical condition is not adequately managed. Studies suggest recurrence rates of approximately 15–30% over long-term follow-up. Maintenance benzodiazepine therapy or periodic ECT may be necessary for patients with recurrent episodes.

Complications of prolonged catatonia include deep vein thrombosis and pulmonary embolism (from immobility), malnutrition and dehydration, aspiration pneumonia, pressure ulcers, rhabdomyolysis, contractures, and long-term functional impairment. These complications are preventable with early treatment and appropriate supportive care.

Full functional recovery — including return to work, school, and social activities — is realistic for many patients, particularly those with mood disorder-related catatonia who receive comprehensive treatment for both the catatonic syndrome and the underlying condition.

Catatonia exists at the intersection of psychiatry and neurology, and understanding its relationship to other conditions is essential for accurate diagnosis and treatment.

Neuroleptic malignant syndrome (NMS) shares numerous features with malignant catatonia, including rigidity, hyperthermia, autonomic instability, and altered consciousness. Many experts consider NMS to be a drug-induced form of malignant catatonia. The primary distinguishing factor is the temporal relationship to dopamine-blocking medication exposure. Both conditions are treated with benzodiazepines and, when necessary, ECT.

Anti-NMDA receptor encephalitis is an autoimmune condition that frequently presents with catatonic features, particularly in young women. It is critical to consider this diagnosis in any young patient presenting with new-onset catatonia, psychosis, seizures, and movement abnormalities. Diagnosis requires antibody testing, and treatment involves immunotherapy.

Serotonin syndrome can produce agitation, rigidity, and autonomic instability that overlap with excited or malignant catatonia. A careful medication history — particularly regarding serotonergic agents — is essential for differentiation.

Bipolar disorder and major depressive disorder are the psychiatric conditions most commonly associated with catatonia. Catatonic features can occur during depressive, manic, or mixed episodes. Recognition of catatonia in these contexts changes treatment fundamentally — benzodiazepines and ECT become priorities, while standard psychiatric medications alone are insufficient.

Schizophrenia historically had the strongest association with catatonia, but modern epidemiological data show that mood disorders are a more frequent context. Nonetheless, the "catatonia specifier" remains an important feature of the DSM-5-TR diagnostic system for schizophrenia.

Autism spectrum disorder (ASD) is increasingly recognized as a risk factor for catatonia, particularly during adolescence and early adulthood. Catatonic-like features in ASD — including slowing, posturing, and reduction in speech — can be particularly challenging to identify, as they may be attributed to the underlying neurodevelopmental condition rather than recognized as a superimposed catatonic syndrome.

Catatonia is a medical and psychiatric emergency that requires prompt professional evaluation. Seek immediate medical attention if you observe any of the following in someone:

• Sudden onset of immobility, mutism, or unresponsiveness in a person who is awake
• Maintaining unusual or rigid postures for extended periods
• Refusal or inability to eat, drink, or speak without clear cause
• Sudden onset of purposeless, uncontrollable motor agitation
• High fever combined with muscle rigidity and altered consciousness
• Repetitive mimicking of others' speech or movements
• Marked opposition or resistance to all instructions or physical guidance

These signs are particularly urgent if the individual has a known history of bipolar disorder, major depressive disorder, schizophrenia, autism spectrum disorder, or a recent change in psychiatric medications — especially the initiation of antipsychotics or withdrawal of benzodiazepines.

Malignant catatonia — characterized by high fever, severe rigidity, autonomic instability, and altered consciousness — is a life-threatening emergency. Call emergency services immediately. Do not wait to see if symptoms improve on their own.

If a loved one with a psychiatric condition begins showing gradual changes such as increasing slowness of movement, reduced speech, new onset of staring, unusual posturing, or progressive withdrawal, bring these concerns to their treatment team promptly. Early intervention can prevent progression to a more severe or dangerous catatonic state.

Even after successful treatment, ongoing psychiatric care is essential to address the underlying condition, prevent recurrence, and support full recovery. Individuals who have experienced catatonia benefit from regular follow-up, medication management, and — in some cases — maintenance ECT or long-term benzodiazepine therapy.